一名复发霍奇金淋巴瘤合并治疗相关骨髓增生异常综合征患者对5-氮杂胞苷的反应 - Suppr

Response to 5-azacytidine in a patient with relapsed Hodgkin Lymphoma and a therapy-related myelodysplastic syndrome.

作者信息

D'Alò Francesco, Leone Giuseppe, Hohaus Stefan, Teofili Luciana, Bozzoli Valentina, Tisi Maria Chiara, Rufini Vittoria, Calcagni Maria Lucia, Voso Maria Teresa

出版信息

Br J Haematol. 2011 Jul;154(1):141-3. doi: 10.1111/j.1365-2141.2010.08438.x. Epub 2011 Feb 20.

DOI:10.1111/j.1365-2141.2010.08438.x

PMID:21332703

Abstract

摘要

相似文献

Response to 5-azacytidine in a patient with relapsed Hodgkin Lymphoma and a therapy-related myelodysplastic syndrome.一名复发霍奇金淋巴瘤合并治疗相关骨髓增生异常综合征患者对5-氮杂胞苷的反应

Br J Haematol. 2011 Jul;154(1):141-3. doi: 10.1111/j.1365-2141.2010.08438.x. Epub 2011 Feb 20.

5'-Azacitidine for therapy-related myelodysplastic syndromes after non-Hodgkin lymphoma treatment.5’-阿扎胞苷治疗非霍奇金淋巴瘤治疗相关骨髓增生异常综合征。

Leuk Res. 2011 Oct;35(10):1409-11. doi: 10.1016/j.leukres.2011.05.030. Epub 2011 Jun 15.

Cytogenetic response is not a prerequisite for clinical response in patients with myelodysplastic syndromes treated with azacitidine.对于接受阿扎胞苷治疗的骨髓增生异常综合征患者，细胞遗传学反应并非临床反应的先决条件。

Eur J Haematol. 2011 Aug;87(2):186-8. doi: 10.1111/j.1600-0609.2011.01653.x.

5'-azacitidine in myelodysplastic syndromes with inversion of chromosome 3.5-氮杂胞苷治疗伴有3号染色体倒位的骨髓增生异常综合征

Leukemia. 2011 Apr;25(4):736-7. doi: 10.1038/leu.2011.6. Epub 2011 Feb 4.

Efficacy of hypomethylating agents in therapy-related myelodysplastic syndromes.低甲基化药物在治疗相关性骨髓增生异常综合征中的疗效。

Leuk Res. 2012 Sep;36(9):1093-7. doi: 10.1016/j.leukres.2012.04.025. Epub 2012 May 17.

Azacitine (vidaza) for myelodysplastic syndrome.阿扎胞苷（维达莎）用于治疗骨髓增生异常综合征。

Med Lett Drugs Ther. 2005 Jan 31;47(1201):11.

FDA drug approval summary: azacitidine (5-azacytidine, Vidaza) for injectable suspension.美国食品药品监督管理局药物批准摘要：注射用阿扎胞苷（5-氮杂胞苷，维达莎）混悬液

Oncologist. 2005 Mar;10(3):176-82. doi: 10.1634/theoncologist.10-3-176.

Is there an association between 5-azacitidine and ototoxicity?5-氮杂胞苷与耳毒性之间是否存在关联？

J Clin Pharmacol. 2010 Sep;50(9):1056-7. doi: 10.1177/0091270009360536. Epub 2010 Mar 16.

Successful treatment of donor cell derived myelodysplastic syndrome with 5-azacytidine.5-氮杂胞苷成功治疗供体细胞衍生的骨髓增生异常综合征

Ann Biol Clin (Paris). 2017 Dec 1;75(6):713-714. doi: 10.1684/abc.2017.1293.

Approval summary: azacitidine for treatment of myelodysplastic syndrome subtypes.批准摘要：阿扎胞苷用于治疗骨髓增生异常综合征亚型。

Clin Cancer Res. 2005 May 15;11(10):3604-8. doi: 10.1158/1078-0432.CCR-04-2135.

引用本文的文献

Advances in Hodgkin Lymphoma Treatment: From Molecular Biology to Clinical Practice.霍奇金淋巴瘤治疗的进展：从分子生物学到临床实践

Cancers (Basel). 2024 May 10;16(10):1830. doi: 10.3390/cancers16101830.

New molecular targets in Hodgkin and Reed-Sternberg cells.霍奇金和里德-斯特恩伯格细胞中的新分子靶点。

Front Immunol. 2023 May 15;14:1155468. doi: 10.3389/fimmu.2023.1155468. eCollection 2023.

Deregulated miRNAs Contribute to Silencing of B-Cell Specific Transcription Factors and Activation of NF-κB in Classical Hodgkin Lymphoma.失调的微小RNA促成经典型霍奇金淋巴瘤中B细胞特异性转录因子的沉默及核因子κB的激活。

Cancers (Basel). 2021 Jun 23;13(13):3131. doi: 10.3390/cancers13133131.

SMAD1 promoter hypermethylation and lack of SMAD1 expression in Hodgkin lymphoma: a potential target for hypomethylating drug therapy.SMAD1启动子高甲基化及霍奇金淋巴瘤中SMAD1表达缺失：低甲基化药物治疗的潜在靶点

Haematologica. 2021 Feb 1;106(2):619-621. doi: 10.3324/haematol.2020.249276.

Outcome of therapy-related myeloid neoplasms treated with azacitidine.阿扎胞苷治疗相关性髓系肿瘤的疗效。

J Hematol Oncol. 2012 Aug 1;5:44. doi: 10.1186/1756-8722-5-44.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Response to 5-azacytidine in a patient with relapsed Hodgkin Lymphoma and a therapy-related myelodysplastic syndrome.

作者信息

出版信息

相似文献

引用本文的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

引用本文的文献